BCHMF
Bachem Holding AG provides products for research, clinical development, and commercial application to pharmaceutical and biotechnology companies worldwide. The company engages in the development, production, and regulatory support of peptide active pharmaceutical ingredients, such as peptide and oligonucleotide new chemical entities (NCEs). It also offers commercial NCEs and generics; and project management, quality and regulatory, analytical, good manufacturing practice production, research grade production, and supply and vertical integration services. The company was founded in 1971 and is headquartered in Bubendorf, Switzerland.
| Period | EPS | Revenue | FCF |
|---|---|---|---|
| 2025 Q4 | 1.32 | $382M | $9M |
| 2025 Q2 | 0.67 | $313M | -$57M |
| 2024 Q4 | 1.12 | $365M | -$74M |
| 2024 Q2 | 0.48 | $240M | -$65M |
| 2023 Q4 | 1.04 | $337M | $15M |
| 2023 Q2 | 0.46 | $240M | -$32M |
| 2022 Q4 | 0.86 | $297M | -$29M |
| 2022 Q2 | 0.50 | $235M | -$20M |